WUHAN, China, Feb. 1, 2023 /PRNewswire/ — NERVTEX’s MoDAS (Movement Dysfunction Assessment Software) system, which is a First-in-Class Synthetic Intelligence/Machine Studying (AI/ML)- based mostly Software as a Medical Device(SaMD) for the evaluation of motor signs of Parkinson’s illness and different motion issues, has been approved by the China Nationwide Medical Merchandise Administration, making it the primary video-based AI-powered medical device for the evaluation of motion issues.
MoDAS makes use of consumer-level sensible cellular units to conveniently seize video of the affected person’s motion standing. By adapting AI applied sciences reminiscent of pc imaginative and prescient and deep studying, MoDAS mechanically offers docs with goal and quantitative info for medical choice assist, relieving docs from time-consuming commentary and analysis, and tremendously enhancing the analysis and therapy effectivity of motion issues reminiscent of Parkinson’s illness. In contrast to wearable movement sensors, MoDAS successfully avoids the interference of bodily units with human motion, eliminates the time consumed by carrying and disinfecting sensors, and reduces the issue and complexity of deployment in medical institutes and first healthcare providers based mostly fully on video evaluation.
In a multi-centre medical research of Parkinson’s illness sufferers led by Shanghai Changhai Hospital, the output results of MoDAS was extremely in step with clinicians’ analysis based mostly on present standards. No opposed occasions had been noticed in sufferers on this research, demonstrating wonderful security and efficacy. In accordance to the specialists concerned within the research, MoDAS matches effectively into the present medical workflow and its cellular design permits entry to graphical information in actual time, enhancing the effectivity and high quality of medical analysis.
In 2021, the AI know-how behind MoDAS was chosen from lots of of initiatives around the globe by the Centre for Innovation in Healthcare of the Nationwide College Healthcare System and the Asian Innovation Analysis Alliance to be a part of the ICP programme for additional exploration of medical utility. Lately, MoDAS was additionally chosen for the checklist of “Top 100 Most Innovative Medical Technology Products of the Year 2022” and “Digital Therapeutics Innovation of the Year” by the VB-Discover Award & VB 100.
The analysis and classification of motion issues, reminiscent of Parkinson’s illness, continues to be based totally on medical commentary by the doctor within the area and evaluation based mostly on the outcomes of quite a few commonplace scales. With the accelerated getting older of the inhabitants in lots of main international locations around the globe, the issues of the normal method, together with the allocation of restricted doctor sources and the low effectivity of analysis and therapy, have turn into more and more obvious. The usage of synthetic intelligence know-how to assist evaluation and therapy is the present hotspot of many firms and analysis establishments around the globe, and its theoretical foundation and sensible use have been absolutely demonstrated in areas reminiscent of pathological evaluation and surgical planning. Within the area of motion issues, synthetic intelligence know-how based mostly on pc imaginative and prescient has apparent benefits and is a sizzling subject of neurological medication innovation in neuroscience around the globe.
Dr Zhou Dong, NERVTEX’s Chief Medical Officer, mentioned: “Movement disorders are probably one of the earliest neurological diseases to be discovered and studied in humans, yet their symptom assessment methods and tools have made little progress for so many years, which to some extent limits progress in disease assessment and treatment, as well as drug development. My team and I have long aspired to provide neurologists with a convenient tool for objective quantification of motor symptoms, just as X-rays are for surgeons, to help them make more accurate and efficient treatment decisions.
“Info know-how, after greater than 50 years of growth, has confirmed its energy and worth to all of humanity. Introducing these applied sciences into the event of the evaluation and therapy of motion issues with MoDAS is a stable and massive step for NERVTEX, and in addition a small step within the large wave of ‘Digital | New Drugs'”. Dong Boya, founder and CEO of NERVTEX, said: “We’re prepared to work with physicians around the globe on this path to the longer term and dedicate ourselves to a more healthy and higher tomorrow.”
NERVTEX is an innovative technology company focused on the research and development of digital therapies for brain disorders. Founded in 2018, the core technology team consists of algorithmic scientists, digital product experts and clinical researchers.
The company has extensive experience in the integration of technology and medicine, such as artificial intelligence, virtual reality and gamified neurorehabitation, and is committed to providing innovative digital medical solutions for clinical experts in neurology and psychiatry.
Headquartered in China, NERVTEX has two Class II medical device approvals, eight national invention patents pending, and more than 20 products in research and registration for various indications.
View unique content material:https://www.prnewswire.com/news-releases/record-short-videos-to-assess-parkinsons-disease-nervtexs-first-in-class-ai-based-movement-dysfunction-assessment-software-medical-device-approved-301736168.html